Cmed Appoints Andrew Kellett as Chief Financial Officer

Cmed Appoints Andrew Kellett as Chief Financial Officer 


HORSHAM, England - (Business Wire) Cmed Group which combines clinical research services with a leading-edge clinical data capture and management system, has strengthened its senior management team with the appointment of Andrew Kellett as Chief Financial Officer (CFO).

Kellett, who was formerly Finance Director of Genetix Group Plc, a global life sciences diagnostics and digital pathology company, brings on board a wealth of experience in the financial management of international high growth companies in the medical sector.

His appointment strengthens Cmed's management team as the group accelerates the global expansion of its flagship IT product Timaeus, a next-generation clinical data capture and management solution which is already delivering critical benefits in a number of major international clinical trials.

Kellett spent four years as CFO at Genetix which was acquired by the Danaher Corporation this year for £63 million and prior to that he was European Finance Director and Global Controller for clinical trials and pharmaceutical business development for US-based Quest Diagnostics Inc, a world-leading diagnostic lab testing company.

He trained at Coopers and Lybrand and has established a strong track record in financial management, operational leadership in diverse, global companies, as well as extensive experience in driving strategic growth, corporate development activities, mergers and acquisitions.

Cmed Chief Executive David Connelly said: "We are delighted to welcome Andrew Kellett to the Cmed team. Andrew joins at a pivotal moment in Cmed's growth and development and brings a wealth of experience in global financial operations and strategy. Andrew's expertise and knowledge of the financial arena will play an essential part in helping us achieve our goals."

Kellett commented: "I am very pleased to be joining CMED at such an exciting time in its development. I am greatly looking forward to working with the CMED team as we further grow the business and realise its full potential."

CMED's innovative clinical data management system Timaeus is being used to capture and manage data in real-time across six continents for a broad range of clinical trials.

Timaeus delivers key advantages over existing data capture and management systems, including enabling professionals working on clinical trials in remote locations (often in the developing world) to manage data reliably and at high speed using only a mobile phone connection. Customers include the Aereas Global TB Vaccine Foundation, which is developing new tuberculosis vaccines currently being trialled in South Africa.

...ENDS...

Notes to Editors

About Cmed - The Cmed Group of companies, formed by pharmaceutical industry executives, is based in Horsham, UK, New Jersey and North Carolina, USA and Timisoara, Romania. Cmed is a unique combination of a full service CRO and an eClinical solutions provider. Cmed CRO offers services across a wide range of therapeutic areas and challenging geographical locations; these include project management, clinical monitoring, clinical data management and biostatistics. Our skilled workforce combines clinical expertise and innovative processes with the Timaeus eClinical platform to deliver a smarter approach to the conduct of clinical trials. Cmed Technology provides Timaeus, a next-generation solution for on-demand trial configuration, EDC, monitoring, medical coding, clinical data management and reporting.

For more information visit: www.cmedresearch.com, www.cmedtechnology.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6421540&lang=en

 


Cmed Media Contact:
Jane Stubbington
[email protected]
01403 756416
 
 

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.